NCT01082328已完成4 期
ENDURE: A Phase IV, Prospective, Open-label, Uncontrolled, Multi-centre Cohort Trial to Assess the Responsiveness of Subjects With Phenylketonuria (PKU) to Treatment With Kuvan® 20 mg/kg/Day for 28 Days
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 1
- 主要终点
- Percentage of Participants With at Least 30 Percent Reduction From Baseline in Blood Phenylalanine (Phe) Level
研究概览
简要总结
The primary objective of the study is to evaluate the proportion of responders (that is, greater than or equal to [>=] 30 percent reduction from Baseline in blood phenylalanine [Phe] level) to treatment with Kuvan® (sapropterin dihydrochloride) 20 milligram per kilogram per day (mg/kg/day) for 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 4 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects aged 4 years or older at the time the informed consent is obtained
- •Subjects diagnosed with PKU (subgroups defined as: classic PKU [blood Phe greater than {>}1200 micromole per liter {mcmol/L}], mild PKU [blood Phe 600 to1200 mcmol/L] or mild hyperphenylalaninemia (HPA) [blood Phe 300 to 600 mcmol/L]
- •Subjects who have received no previous treatment with sapropterin dihydrochloride (either Kuvan® or any other formulations of tetrahydrobiopterin [BH4])
- •Subjects adherent to their normal diet and willing to adhere to the given diet for the 4 weeks study period
- •Subjects who provide a signed (by parent if below 18 years) written informed consent
- •Subjects with documented genotyping for both phenylalanine hydroxylase (PAH) mutations (PKU genotype)
- •Phenylketonuria (PKU) diagnosis should be documented with at least two historical blood Phe levels above 400 mcmol/L
- •Female subjects of childbearing potential (and, if appropriate, male subjects with female partners of childbearing potential) must be willing to avoid pregnancy by using an adequate method of contraception (defined as two barrier methods or one barrier method with spermicide, or intrauterine device or use of the oral female contraceptive) for 4 weeks prior to, during and 12 weeks after the last dose of trial medication
- •Women of childbearing potential (for the purpose of this trial, women of childbearing potential are defined as "All female subjects after puberty unless they are post-menopausal for at least 2 years, are surgically sterile or are sexually inactive") must have a negative urine pregnancy test at the Baseline visit
排除标准
- •Subjects who have documented BH4 deficiency
- •Subjects who have any contraindications to receive Kuvan® as outlined in the summary of product characteristics (SmPC) not willing or able to comply with the study procedures
- •Subjects who are pregnant, planning for pregnancy or breastfeeding
- •Subjects who have been exposed to any investigational medicinal drugs or treatments within 30 days or 5 half-lives, whichever is longer, prior to the Screening visit
- •Subjects using concomitant treatment with folate synthesis inhibiting drugs
- •Subjects with concurrent use of Levodopa
- •Subjects with concurrent use of inhibitors of dihydrofolate reductase (for example, methotrexate, trimethoprim)
- •Subjects with concurrent use of agents that cause vasodilation, including those administered topically, by affecting nitric oxide (NO) metabolism or action including classical NO donors (for example, glyceryl trinitrate (GTN), isosorbide dinitrate (ISDN), sodium nitroprusside (SNP), molsidomin), phosphodiesterase type 5 (PDE-5) inhibitors and minoxidil
- •Subjects who have a concurrent disease potentially interfering safety (for example, seizure disorder, oral steroid dependent asthma, other conditions requiring systemic corticosteroids, or insulin-dependent diabetes mellitus)
- •Subjects who have inadequate liver function, defined by alanine aminotransferase (ALT) >= 2 times upper limit of normal (ULN)
- •Subjects who have clinically significant renal dysfunction, defined by serum creatinine > 250 mcmol/L
- •Have any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to study drug or would significantly interfere with the subject's ability to comply with the provisions of the protocol
研究组 & 干预措施
Kuvan®
Experimental
干预措施: Kuvan® (Drug)
结局指标
主要结局
Percentage of Participants With at Least 30 Percent Reduction From Baseline in Blood Phenylalanine (Phe) Level
时间窗: Baseline up to Day 28 +/- 1
Response to treatment was defined as 30 percent reduction from Baseline in blood phenylalanine (Phe) Level during the 28 +/- 1 days.
次要结局
- Number of Participants With Adverse Events (AEs), Treatment Emergent Adverse Events, Treatment Related Adverse Events and AEs Leading to Withdrawal(Baseline up to Day 42 +/- 3)
- Percentage of Early-, Late-, Partial-Responders and Non-responders to Treatment With Kuvan®(Baseline up to Day 28 +/- 1)
- Percentage of Participants With Greater Than or Equal to (>=) 30 Percent, 20 to 30 Percent, 10 to 20 Percent and Less Than (<) 10 Percent Reduction in Blood Phe Levels According to Phenylketonuria (PKU) Phenotypes(Baseline up to Day 28 +/- 1)
- Percentage of Early-, Late- and Partial-Responders According to Phenotype(Baseline up to Day 28 +/- 1)
- Mean Change From Baseline in Blood Phenylalanine-to-tyrosine Ratio(Baseline, Day 28)
研究者
研究点 (1)
Loading locations...
相似试验
终止
4 期
Thyroid Function of Pediatric Subjects Following Isovue® AdministrationHypothyroidismNCT03779906Bracco Diagnostics, Inc17
已完成
2 期
Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and NeckSquamous Cell Carcinoma of Head and NeckNCT02061631Sanofi35
Unknown
2 期
Pazopanib in Second-line Therapy in Renal Cell CarcinomaMetastatic Renal Cell CarcinomaNCT01577784Associació per a la Recerca Oncologica, Spain27
已完成
4 期
A Study of Filgotinib in Korean Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT06625242Eisai Korea Inc.118
已完成
2 期
JAK-inhibition in Recurrent Classical Hodgkin LymphomaRecurrent Classical Hodgkin LymphomaNCT02164500University of Cologne12